1.82
-0.08 (-4.21%)
| Penutupan Terdahulu | 1.90 |
| Jumlah Dagangan | 2,972,646 |
| Harga / Jualan (P/S) | 269.28 |
| Harga / Buku (P/B) | 2.06 |
| Julat 52 Minggu |
| Margin Operasi (TTM) | -7,273.06% |
| EPS Cair (TTM) | -0.400 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 5.79% |
| Nisbah Semasa (MRQ) | 8.33 |
| Aliran Tunai Operasi (OCF TTM) | -44.17 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -25.01 M |
| Pulangan Atas Aset (ROA TTM) | -26.41% |
| Pulangan Atas Ekuiti (ROE TTM) | -41.31% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Compass Therapeutics, Inc. | Bercampur | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 0.5 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | -2.5 |
| Purata | -0.67 |
|
Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to drug the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-IO Bispecific, and CTX-8371. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 14.16% |
| % Dimiliki oleh Institusi | 67.95% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Enavate Sciences Gp, Llc | 30 Jun 2026 | 7,788,150 |
| Vivo Capital, Llc | 30 Jun 2026 | 7,757,060 |
| Palo Alto Investors Lp | 30 Jun 2026 | 5,831,813 |
| Blue Owl Capital Holdings Lp | 30 Jun 2026 | 3,624,076 |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |